Trial Profile
Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 22 Feb 2021 Planned End Date changed from 29 Sep 2020 to 31 Dec 2021.
- 22 Feb 2021 Planned primary completion date changed from 29 Sep 2020 to 31 Dec 2021.